本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Apellis Pharmaceuticals Inc.

28.13
-0.5200-1.82%
盘后28.500.3700+1.32%17:29 EDT
成交量:281.01万
成交额:7,960.38万
市值:35.53亿
市盈率:-15.42
高:28.97
开:28.84
低:27.85
收:28.65
52周最高:41.94
52周最低:16.10
股本:1.26亿
流通股本:7,811.99万
量比:1.47
换手率:3.60%
股息:- -
股息率:- -
每股收益(TTM):-1.8245
每股收益(LYR):-1.5970
净资产收益率:-108.49%
总资产收益率:-13.77%
市净率:22.73
市盈率(LYR):-17.61

数据加载中...

2024/03/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/08

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/29

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/02/27

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities